Mechanism of action of progesterone antagonists

被引:130
|
作者
Leonhardt, SA
Edwards, DP
机构
[1] Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Pathol B216, Denver, CO 80262 USA
[2] Univ Colorado, Hlth Sci Ctr, Sch Med, Program Mol Biol, Denver, CO 80262 USA
关键词
progesterone; progesterone receptor; steroidal antagonists; RU486; nonsteroidal antagonists;
D O I
10.1177/153537020222701104
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The effects of progesterone on target tissues are mediated by progesterone receptors (PRs), which belong to a family of nuclear receptors and function as ligand-activated transcription factors to regulate the expression of specific sets of target genes. Progesterone antagonists repress the biological actions of progesterone by "actively" inhibiting PR activation. This work discusses the first clinically used progesterone antagonist RU486 and closely related compounds in terms of how these compounds inhibit progesterone action through heterodimerization and competition for DNA binding and by e recruitment of corepressors to promoters of target genes to repress transcription. We discuss cellular factors that may influence the activity of these compounds, such as the availability of coactivators and corepressors and the context of specific target promoters in any given cell type. We also discuss steroidal and nonsteroidal antagonist selectivity for PR versus other steroid hormone receptors and suggest that it may be possible to develop tissue/cell specific modulators of PR.
引用
收藏
页码:969 / 980
页数:12
相关论文
共 50 条
  • [41] Mechanism of action and clinical development of platelet thrombin receptor antagonists
    Ueno, Masafumi
    Ferreiro, Jose Luis
    Angiolillo, Dominick J.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2010, 8 (08) : 1191 - 1200
  • [42] ADRENERGIC PRESYNAPTIC ANTAGONISTS AND THEIR MECHANISM OF ACTION IN SMOOTH-MUSCLE
    KALSNER, S
    AMERICAN JOURNAL OF PHYSIOLOGY, 1992, 262 (03): : R400 - R406
  • [44] THE ACTION MECHANISM OF CALCIUM-ANTAGONISTS IN THE SMOOTH VASCULAR MUSCULATURE
    KOLLING, K
    ERNST, M
    RIEMER, J
    ZEITSCHRIFT FUR KARDIOLOGIE, 1986, 75 : 126 - 126
  • [45] Progesterone receptor antagonists (antiprogestins)
    Hess-Stumpp, H
    Hoffmann, J
    Fuhrmann, U
    DRUGS OF THE FUTURE, 2002, 27 (11) : 1113 - 1123
  • [46] POTENTIATION OF THE IMMUNOSUPPRESSIVE ACTION OF CYCLOSPORINE-A (CSA) BY PAF ANTAGONISTS - AN APPROACH OF THE MECHANISM OF ACTION
    BRAQUET, P
    PIGNOL, B
    HENANE, S
    PIROTZKY, E
    MENCIAHUERTA, JM
    PROSTAGLANDINS, 1987, 34 (02): : 198 - 198
  • [47] The use of progesterone antagonists and progesterone receptor modulators in contraception
    Spitz, IM
    Van Look, PFA
    Bennink, HJTC
    STEROIDS, 2000, 65 (10-11) : 817 - 823
  • [48] DIFFERENTIATION THERAPY WITH PROGESTERONE ANTAGONISTS
    MICHNA, H
    PARCZYK, K
    SCHNEIDER, MR
    NISHINO, Y
    STEROID RECEPTORS AND ANTIHORMONES, 1995, 761 : 224 - 247
  • [49] Progesterone receptor agonists and antagonists
    Allan, G
    Macielag, M
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1999, 9 (07) : 955 - 962
  • [50] ACTION OF ANTAGONISTS AND COMBINATIONS OF ANTAGONISTS
    ARIENS, EJ
    SIMONIS, AM
    ACTA PHYSIOLOGICA ET PHARMACOLOGICA NEERLANDICA, 1965, 13 (02): : 181 - &